EVOKE PHARMA INC's ticker is EVOK and the CUSIP is 30049G104. A total of 28 filers reported holding EVOKE PHARMA INC in Q1 2021. The put-call ratio across all filers is 0.16 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $77,000 | -49.0% | 30,062 | -7.2% | 0.00% | -100.0% |
| Q3 2020 | $151,000 | +32.5% | 32,387 | 0.0% | 0.00% | – |
| Q2 2020 | $114,000 | +208.1% | 32,387 | 0.0% | 0.00% | – |
| Q1 2020 | $37,000 | -28.8% | 32,387 | 0.0% | 0.00% | – |
| Q4 2019 | $52,000 | +92.6% | 32,387 | 0.0% | 0.00% | – |
| Q3 2019 | $27,000 | +35.0% | 32,387 | 0.0% | 0.00% | – |
| Q2 2019 | $20,000 | -58.3% | 32,387 | 0.0% | 0.00% | – |
| Q1 2019 | $48,000 | -40.0% | 32,387 | 0.0% | 0.00% | – |
| Q4 2018 | $80,000 | -16.7% | 32,387 | 0.0% | 0.00% | – |
| Q3 2018 | $96,000 | -6.8% | 32,387 | -21.7% | 0.00% | -100.0% |
| Q2 2018 | $103,000 | +53.7% | 41,387 | +27.8% | 0.00% | – |
| Q1 2018 | $67,000 | -8.2% | 32,387 | 0.0% | 0.00% | – |
| Q4 2017 | $73,000 | – | 32,387 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 242,500 | $1,962,000 | 1.69% |
| SOPHROSYNE CAPITAL LLC | 49,000 | $397,000 | 0.40% |
| LMR Partners LLP | 23,882 | $187,000 | 0.02% |
| GEODE CAPITAL MANAGEMENT, LLC | 10,276 | $80,000 | 0.00% |
| BlackRock Investment Management, LLC | 489 | $4,000 | 0.00% |
| MORGAN STANLEY | 500 | $4,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 84 | $1,000 | 0.00% |
| VANGUARD GROUP INC | 48,394 | $378,000 | 0.00% |
| UBS AG | 727 | $6,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 33,500 | $271,000 | 0.00% |